Skip to main content

  | मौसम…

411 समाचार
Public archive edition · Attributed source reporting with original dates · AI drafts are excluded

411 REFERENCE · Wikibooks

Radiation Oncology/Rectum/Guidelines

Reference material by Wikibooks contributors. This retains its source identity and is not 411 news reporting.

Rectal Cancer Official Guidelines Screening ACS: Colorectal Cancer: Early Detection Guideline link Joint Consensus Guideline: Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps From ACS, ACR, and US Multi-Society Task Force 2008 Guideline link 18384785 Tumor Markers ASCO: Use of Tumor Markers in GI Malignancies 2006 Guideline link 17060676 -- "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer." (Locker GY, J Clin Oncol. 2006 Nov 20;24(33):5313-27.) Treatment ACR: Local Excision in Early Stage Rectal Cancer Guideline link ACR: Rectal Cancer—Metastatic Disease at Presentation Guideline link ACR: Recurrent Rectal Cancer Guideline link ACR: Resectable Rectal Cancer Guideline link Contouring Guidelines RTOG Atlas RTOG Anorectal Contouring Guidelines 2009 19117696 -- "Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas." (Myerson RJ, Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30. Epub 2008 Dec 29.) 2011 20400244 -- "Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting." (Fuller CD, Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):481-9. Epub 2010 Apr 18.) Randomized. 1 rectal case, 14 physicians and one reference expert countouring. Arm 1) consensus guideline vs Arm 2) no consensus guideline. Two contours, pre- and post. Outcome: Greater agreement for GTV (0.75) than for CTVs (0.46 - 0.65). For consensus guideline group, only improvement after reviewing atlas was for CTVA, no impact on GTV and CTVB contours Conclusion: Visual atlas inclusion should be considered in clinical trials